TEI Biosciences Inc.

Products for spinal, cardiovascular, neurosurgical, skin, urological, cosmetic, and general orthopaedic applications using industrial textile manufacturing methods to create collagen-based tissue scaffolds and methods for enriching these scaffolds

Privately-held biomedical company, founded by Dr. Eugene Bell, Professor Emeritus of Biology at MIT. The companh began operations upon receipt of an award from NIST. In July 1999, TEI Biosciences entered into an investment and development agreement with Medtronic, Inc., for the development of certain products in the neurological, cardiovascular, and spinal fields. In 2002, the company received 510(k) clearance from the FDA to market their proprietary EBM soft tissue repair matrix as a surgical mesh for the repair or reinforcement of soft tissues.

Yiannis Monovoukas, Dr., Chairman, President and CEO
Robert Buehler, PhD, Vice President, Manufacturing and Operations
Kenneth James, PhD, Vice President, Product Sciences and Regulatory Affairs

Yiannis Monovoukas, PhD, MBA, Chairman
Anthony S. Bell
Rebecca M. Bergman
Lewis H. Ferguson, III, Esq.
John N. Hatsopoulos
Leonard Laster, MD, Prof.

7 Elkins Street
Boston, MA 02127
USA
Phone: +1-617-268-1616
Fax: +1-617-268-3282

The company’s EBM is a strong, animal-derived, highly biocompatible, remodelable collagen membrane. The membrane has been cleared by the FDA and is CE-marked for use as a surgical mesh covering. The mesh covers a broad spectrum of tissue repair applications including rotator cuff, dura, pelvic floor reconstruction, skin wounds and urogynaecological conditions. EBM can be remodelled over time by the body into a functional tissue. It has sites for rapid and specific cell attachment and for binding cell-secreted products.

Engineered devices include TissueMend®, Durepair®, Cytrix™, DressSkin™, and SurgiMend™. TissueMend® was launched in the U.S. in August 2003 and is marketed by Stryker Orthopaedics. Durepair® was launched in Europe in April 2004 and is marketed by Medtronic Neurosurgery.

In addition, the company is focused on proprietary cell-signaling complexes (Signal-plexes™), which the company has shown in the lab to accelerate tissue repair and direct the differentiation of stem cells.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.